RE:RE:RE:TodaySorry, Laser, respectfully disagree on timelines and the need for jumping through more hoops. Of course, pharma would like us to jump through those hoops and we accept all the risk and they none!!! Fuk that submissive position and hat in hand approach!!!! We need to be loud and proud!! I know most of the posters believe in us, believe in our results, believe in our future!!!! Why should we accept all the risk now!! Why are we not sharing that risk with a jv?? They wont accept it???? Are we a high risk, extremely high reward investment?? Absolutely we r!!! We have done enough luring and our results are amazin, no matter how suppressed they have been manipulated, pharma knows who we r and what we possibly have.
Now, Roger can continue to have shareholders accept all the risk and ignore pharma, or he can say, ok, its time for a boatload of money that allows us to continue on with all the amazin things we r currently involved in and want to start soon, and we want to share some of that risk!!! Only one way of doing that, bring pharma on board. There is no other option that gets us to market sooner and saves lives quicker!
What are we waiting for??? The holy trinity to speak to us??? Well, lets take bets, who speaks first, the holy trinity, or Roger??????
LaserStock29 wrote: Pandora wrote: I sent an email to these guys suggesting they could try a roll-over combination with TLD1433 and as normal did not even get a response -- the Theralase name is not quite as recognized as Merck and Bristol-Myers Squibb.
Briacell (V.BCT)
...The company is currently conducting a Phase I/IIa clinical trial for Bria-IMT™ in patients with advanced breast cancer. This trial is listed in ClinicalTrials.gov as NCT03066947. The trial is being conducted along with the co-development of BriaDX™, the Company’s companion diagnostic test. The interim data for the first 10 patients is expected by the first quarter of 2018. Additionally, the FDA recently approved the roll-over combination study of Bria-IMT™ with pembrolizumab [Keytruda®; manufactured by Merck & Co., Inc.] or ipilimumab [Yervoy®; manufactured by Bristol-Myers Squibb Company] for patients previously treated with Bria-IMT™ in the Company’s ongoing Phase I/IIa clinical trial in advanced breast cancer. The roll-over trial is listed in ClinicalTrials.gov as NCT03328026.
Nice iniative :-) But here at home we have the best hospital and backing of doctors doing much releated and relevant clinical trial
Ie. Dr.Yasufuku in 'First Line' with Concordia for 'Photofrin + Laser'
PDT LUNG I mean who knows...
Just wait until P9... ... death_metal already posted the 'deal' with merck..... iv'e laid out the fda conditional nod scenario........
theres not much else lol...
Looking forward to 9/9 perfecto.